Rafael Holdings, Inc. (RFL) Stock Price & Analysis
Rafael Holdings, Inc. (RFL) rose 3.64% to USD 2.56 as of September 8, 2026 at 07:34 UTC, according to Nexqual real-time market data.
RFL last closed at USD 2.47; the session ranged USD 2.5–2.74 on volume of 138,485 shares. Market capitalization is $133.12M, with a 52-week range of USD 1.12–3.96 (NYQ). Source: Nexqual, September 8, 2026 at 07:34 UTC.
Key Statistics (as of September 8, 2026 at 07:34 UTC)
| Price | USD 2.56 |
|---|---|
| Change | ▲ 3.64% (up) |
| Previous Close | USD 2.47 |
| Open | USD 2.49 |
| Day Range | USD 2.5 – 2.74 |
| 52-Week Range | USD 1.12 – 3.96 |
| Volume | 138,485 shares |
| Market Cap | $133.12M |
| Exchange | NYQ |
Technical Analysis (RFL)
Nexqual's technical model rates RFL "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 07:34 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 63.02 (neutral) |
| vs SMA50 | Above (USD 2.29) |
| MACD | 0.12 (positive) |
Analyst Ratings (RFL)
Wall Street analysts rate RFL "None", per Nexqual as of September 8, 2026 at 07:34 UTC.
| Consensus Rating | None |
|---|
Earnings (RFL)
| Next Earnings Date | 2026-10-28 |
|---|
Source: Nexqual, September 8, 2026 at 07:34 UTC.
Financials & Fundamentals (RFL)
| Total Revenue | $980,000 |
|---|---|
| Revenue Growth (YoY) | -50.60% |
| Gross Margin | +95.10% |
| Operating Margin | -3837.99% |
| Profit Margin | +0.00% |
| ROE | -37.59% |
| Debt / Equity | 0.76 |
| Current Ratio | 3.16 |
| Total Cash | $30.50M |
| Total Debt | $610,000 |
| Free Cash Flow | $-20.67M |
Source: Nexqual, September 8, 2026 at 07:34 UTC.
Financial Health Score (RFL)
Nexqual rates Rafael Holdings, Inc.'s overall financial health "Weak" across five dimensions, as of September 8, 2026 at 07:34 UTC.
| Growth | Critical — Revenue -51% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $30M cash, no debt |
| Cash Flow | Weak — FCF negative: -$21M, burning cash |
| Efficiency | Critical — ROE -38%, ROA -22.8% |
Ownership (RFL)
| Insider Ownership | +38.23% |
|---|---|
| Institutional Ownership | +8.10% |
| Shares Outstanding | 51.21M |
| Float | 31.77M |
| Short % of Float | +1.85% |
Source: Nexqual, September 8, 2026 at 07:34 UTC.
Leadership (RFL)
Rafael Holdings, Inc. is led by Howard S. Jonas (age 69), CEO, President, Founder & Executive Chairman, per Nexqual as of September 8, 2026 at 07:34 UTC.
| CEO, President, Founder & Executive Chairman | Howard S. Jonas (age 69) |
|---|---|
| Chief Financial Officer | David A. Polinsky (age 53) |
| Chief Operating Officer | Joshua M. Fine (age 43) |
Major Backers & Investors (RFL)
Notable institutional backers of Rafael Holdings, Inc. include Fidelity, IEQ Capital, LLC, Kahn Brothers Group Inc., according to Nexqual as of September 8, 2026 at 07:34 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 0.65% |
| IEQ Capital, LLC | 0.32% |
| Kahn Brothers Group Inc. | 0.29% |
| DFA INVESTMENT DIMENSIONS GROUP INC-U.S. Micro Cap Portfolio | 0.26% |
| Jane Street Group, LLC | 0.22% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 5.67% |
| BlackRock | 0.97% |
| Geode Capital | 0.84% |
| Dimensional Fund Advisors | 0.59% |
| State Street | 0.31% |
Source: Nexqual, September 8, 2026 at 07:34 UTC.
From Rafael Holdings, Inc.'s Latest SEC 10-K Filing (filed 2025-10-29)
Key Strengths & Strategy (as disclosed to the SEC)
- Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel.
- It operates in three segments, Healthcare, Infusion Technology, and Real Estate.
- The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells.
- Its lead drug candidate is Trappsol Cyclo, which is in phase 3 clinical trial being evaluated for the potential treatment of Niemann-Pick Disease Type C1 ("NPC1"), a rare, fatal and progressive genetic disorder; and CPI-613 (devimistat), a stable analog of normally transient, acylated catalytic intermediates of lipoate, which is in phase II of clinical trial.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| HBB | Hamilton Beach Brands Holding C | USD 31 | ▼ 1.62% |
| VRCA | Verrica Pharmaceuticals Inc. | USD 5.3 | ▼ 1.67% |
| APYX | Apyx Medical Corporation | USD 3.05 | ▼ 0.97% |
| EVLO | Evelo Biosciences, Inc. | USD 0 | ▲ 0% |
| BYSI | BeyondSpring, Inc. | USD 0.62 | ▲ 1.16% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 07:34 UTC. This page is informational and not investment advice.